Patient characteristics at baseline
| . | PV (n = 15) . | PVR (n = 10) . | Total (N = 25) . |
|---|---|---|---|
| Age in y, median (range) | 66 (49-77) | 69 (39-78) | 66 (39-78) |
| Sex, n (%) | |||
| Female | 2 (13) | 3 (30) | 5 (20) |
| Male | 13 (87) | 7 (70) | 20 (80) |
| ECOG PS | |||
| 0 | 7 (47) | 7 (70) | 14 (56) |
| 1 | 8 (53) | 3 (30) | 11 (44) |
| Mutation status, n (%)∗ | |||
| BTK C481 mutant | 6 (40) | 3 (38) | 9 (39) |
| BTK C481 wild type | 9 (60) | 5 (63) | 14 (61) |
| PLCG2 mutation status, n (%)† | |||
| Yes | 1 (7) | 0 (0) | 1 (4) |
| No | 14 (93) | 8 (100) | 22 (96) |
| del(17p) by FISH, n (%)‡ | |||
| Yes | 1 (9) | 3 (33) | 4 (20) |
| No | 10 (91) | 6 (67) | 16 (80) |
| TP53 mutation status, n (%)§ | |||
| Mutated | 3 (20) | 3 (38) | 6 (26) |
| Unmutated | 12 (80) | 5 (63) | 17 (74) |
| del(17p) and/or TP53 mutation status, n (%)|| | |||
| Yes | 3 (27) | 4 (50) | 7 (37) |
| No | 8 (73) | 4 (50) | 12 (63) |
| del(11q) by FISH, n (%)¶ | |||
| Yes | 4 (36) | 4 (44) | 8 (40) |
| No | 7 (63) | 5 (56) | 12 (60) |
| IGHV mutation status, n (%)# | |||
| Mutated | 3 (27) | 1 (11) | 4 (20) |
| Unmutated | 8 (73) | 8 (89) | 16 (80) |
| Prior lines of systemic therapy, median (range) | |||
| All therapies | 1 (1-2) | 2 (1-4) | 2 (1-4) |
| BTKi therapies | 1 (0-1) | 1 (0-2) | 1 (0-2) |
| Prior therapies, n (%) | |||
| Anti-CD20 antibody∗∗ | 11 (73) | 7 (70) | 18 (72) |
| BTKi | 11 (73) | 6 (60) | 17 (68) |
| Chemotherapy | 8 (53) | 6 (60) | 14 (56) |
| PI3K agent | 1 (7) | 2 (20) | 3 (12) |
| Reasons for BTKi discontinuation, n (%)†† | |||
| Progressive disease | 8 (73) | 4 (67) | 12 (71) |
| Toxicity | 3 (27) | 2 (33) | 5 (29) |
| . | PV (n = 15) . | PVR (n = 10) . | Total (N = 25) . |
|---|---|---|---|
| Age in y, median (range) | 66 (49-77) | 69 (39-78) | 66 (39-78) |
| Sex, n (%) | |||
| Female | 2 (13) | 3 (30) | 5 (20) |
| Male | 13 (87) | 7 (70) | 20 (80) |
| ECOG PS | |||
| 0 | 7 (47) | 7 (70) | 14 (56) |
| 1 | 8 (53) | 3 (30) | 11 (44) |
| Mutation status, n (%)∗ | |||
| BTK C481 mutant | 6 (40) | 3 (38) | 9 (39) |
| BTK C481 wild type | 9 (60) | 5 (63) | 14 (61) |
| PLCG2 mutation status, n (%)† | |||
| Yes | 1 (7) | 0 (0) | 1 (4) |
| No | 14 (93) | 8 (100) | 22 (96) |
| del(17p) by FISH, n (%)‡ | |||
| Yes | 1 (9) | 3 (33) | 4 (20) |
| No | 10 (91) | 6 (67) | 16 (80) |
| TP53 mutation status, n (%)§ | |||
| Mutated | 3 (20) | 3 (38) | 6 (26) |
| Unmutated | 12 (80) | 5 (63) | 17 (74) |
| del(17p) and/or TP53 mutation status, n (%)|| | |||
| Yes | 3 (27) | 4 (50) | 7 (37) |
| No | 8 (73) | 4 (50) | 12 (63) |
| del(11q) by FISH, n (%)¶ | |||
| Yes | 4 (36) | 4 (44) | 8 (40) |
| No | 7 (63) | 5 (56) | 12 (60) |
| IGHV mutation status, n (%)# | |||
| Mutated | 3 (27) | 1 (11) | 4 (20) |
| Unmutated | 8 (73) | 8 (89) | 16 (80) |
| Prior lines of systemic therapy, median (range) | |||
| All therapies | 1 (1-2) | 2 (1-4) | 2 (1-4) |
| BTKi therapies | 1 (0-1) | 1 (0-2) | 1 (0-2) |
| Prior therapies, n (%) | |||
| Anti-CD20 antibody∗∗ | 11 (73) | 7 (70) | 18 (72) |
| BTKi | 11 (73) | 6 (60) | 17 (68) |
| Chemotherapy | 8 (53) | 6 (60) | 14 (56) |
| PI3K agent | 1 (7) | 2 (20) | 3 (12) |
| Reasons for BTKi discontinuation, n (%)†† | |||
| Progressive disease | 8 (73) | 4 (67) | 12 (71) |
| Toxicity | 3 (27) | 2 (33) | 5 (29) |
Total percentage might be different than the sum of the individual components because of rounding. Molecular features were analyzed by a central research laboratory. Percentages were calculated for patients with available data.
BTKi, Bruton tyrosine kinase inhibitor; ECOG PS, Eastern Cooperative Oncology Group Performance Status; FISH, fluorescence in situ hybridization; IGHV, immunoglobulin heavy variable; PI3K, phosphatidylinositol 3-kinase.
2 patients had missing data (PV: 0; PVR: 2).
2 patients had missing data (PV: 0; PVR: 2).
5 patients had missing data (PV: 4; PVR: 1).
2 patients had missing data (PV: 0; PVR: 2).
6 patients had missing data (PV: 4; PVR: 2).
5 patients had missing data (PV: 4; PVR: 1).
5 patients had missing data (PV: 4; PVR: 1).
Includes both patients who had anti-CD20 as monotherapy and as combination therapy.
Calculated as the percentage of patients who received prior BTK inhibitor. If >1 reason was noted for discontinuation, disease progression took priority.